The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have with Advanced NRAS-Mutated Melanoma. The purpose of this part of the study is to find out how OKI-179 will absorb in the human body when taken with binimetinib, what side effects happen, and whether the drugs have an effect on the cancer.OKI-179 and binimetinib are both drugs that act against a specific enzyme in the body involved in helping cancer cells live and grow.

The University of Virginia Comprehensive Cancer Center seeks patients ages 18 and over with muscle invasive bladder cancer (MIBC) who are not candidates for standard of care chemotherapy for a research study. The purpose of this study is to compare erdafitinib alone to using the combination of erdafitinib and atezolizumab. Erdafitinib and atezolizumab are not approved for the treatment of MIBC, though erdafitinib is FDA approved to treat some metastatic bladder cancers. This study will help determine if the combination of erdafitinib and atezolizumab is better than erdafitinib alone.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have cancers with a specific mutation and have locally advanced or metastatic solid tumors. The purpose of this study is to test an investigational drug called SPYK04 to find out if it’s safe and to understand the way your body processes SPYK04.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The purpose of the study is to evaluate the efficacy and safety of the combination of retifanlimab and INCAGN02385 (treatment group 2), and retifanlimab and INCAGN02385 and INCAGN02390 (treatment group 3), compared to retifanlimab alone (treatment group 1) as first-line treatment for patients with SCCHN.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have melanoma. This study is being done to answer the following questions: Is a 1-centimeter margin as good as a 2-centimeter margin at reducing the risk of melanoma returning? Does having less than a 2-centimeter margin of skin removed cause fewer side effects and improve quality of life?

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas. This study is divided into 2 parts: 1) Part A-Dose Escalation and (2) Part B-Cohort Expansion. You will participate in either Part A or Part B depending on when you join the study. The purpose of this study is to find out if various doses of DR-01 can be safely given to subjects with large granular lymphocytic leukemia or cytotoxic lymphomas and if it will result in destroying your cancer cells.

The University of Virginia, Department of Diabetes Technology, seeks adults between the ages of 18-70 who have Type 1 Diabetes to participate in a clinical study. The purpose of this study is to test a Web-Based Information Tool (WIT). This software will provide additional information regarding your hypoglycemic risk, your hyperglycemia risks, your daily glycemic profile, and may suggest potential changes to your insulin parameters. You will continue to use your Tandem insulin pump with Control-IQ Technology, and you will be trained how to use and interact with WIT.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have advanced or metastatic Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that has become resistant to platinum-based therapy. Eligible participants enrolled in this study will be randomly assigned to 1 of 4 available treatments.

• Arm 1: Nemvaleukin in combination with pembrolizumab
• Arm 2: Pembrolizumab monotherapy
• Arm 3: Nemvaleukin monotherapy
• Arm 4: Investigator’s choice chemotherapy

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have Metastatic Castration-Resistant Prostate Cancer (mCRPC). The purpose of this study is to assess the safety and tolerability (good and bad effects) and how prostate cancer responds to two different doses of the investigational study drug (ARV-766) in men with metastatic cancer of the prostate who have progressed on prior approved systemic therapies for disease like yours (one of which must be enzalutamide, darolutamide, apalutamide or abiraterone).

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have a disease, called light chain (AL) amyloidosis, in which protein builds up through your body. The purpose of the study is to evaluate the safety and tolerability of venetoclax, MLN9708 (ixazomib citrate), and dexamethasone when used in combination for patients who have been previously treated for this disease but did not respond or have progressed. The study will test different doses of the drug to see which dose is safer for people.